Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Stathis

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Cancer Treatment and Research|February 7, 2015
Management of the marginal zone lymphomasBarbara Vannata, Anastasios Stathis, Emanuele Zucca
Current Oncology Reports|February 5, 2019
BET and EZH2 Inhibitors: Novel Approaches for Targeting CancerSofia Genta, Maria Cristina Pirosa, Anastasios Stathis
Human Vaccines & Immunotherapeutics|February 1, 2024
Tafasitamab for the treatment of patients with diffuse large B-cell lymphomaMaria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatmentSofia Genta, Federica Martorana, Anastasios Stathis, et al.
Pharmacology & Therapeutics|April 20, 2020
An overview on anti-tubulin agents for the treatment of lymphoma patientsMarilia Barreca, Anastasios Stathis, Paola Barraja, et al.
International Journal of Molecular Sciences|February 9, 2020
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?Chiara Tarantelli, Antonio Lupia, Anastasios Stathis, et al.
Hematology/Oncology Clinics of North America|October 29, 2008
Marginal zone lymphomasEmanuele Zucca, Francesco Bertoni, Anastasios Stathis, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisRoberta Noseda, Lara Magro, Anastasios Stathis, et al.
Exploration of Targeted Anti-Tumor Therapy|July 5, 2024
Antibody-drug conjugates combinations in cancer treatmentGiulia Pretelli, Kleida Mati, Lucia Motta, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2025
SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone LymphomaMaria Cristina Pirosa, Anastasios Stathis, Davide Rossi, et al.
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Cancer Treatment and Research|February 7, 2015
Management of the marginal zone lymphomasBarbara Vannata, Anastasios Stathis, Emanuele Zucca
Current Oncology Reports|February 5, 2019
BET and EZH2 Inhibitors: Novel Approaches for Targeting CancerSofia Genta, Maria Cristina Pirosa, Anastasios Stathis
Human Vaccines & Immunotherapeutics|February 1, 2024
Tafasitamab for the treatment of patients with diffuse large B-cell lymphomaMaria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatmentSofia Genta, Federica Martorana, Anastasios Stathis, et al.
Pharmacology & Therapeutics|April 20, 2020
An overview on anti-tubulin agents for the treatment of lymphoma patientsMarilia Barreca, Anastasios Stathis, Paola Barraja, et al.
International Journal of Molecular Sciences|February 9, 2020
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?Chiara Tarantelli, Antonio Lupia, Anastasios Stathis, et al.
Hematology/Oncology Clinics of North America|October 29, 2008
Marginal zone lymphomasEmanuele Zucca, Francesco Bertoni, Anastasios Stathis, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisRoberta Noseda, Lara Magro, Anastasios Stathis, et al.
Exploration of Targeted Anti-Tumor Therapy|July 5, 2024
Antibody-drug conjugates combinations in cancer treatmentGiulia Pretelli, Kleida Mati, Lucia Motta, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2025
SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone LymphomaMaria Cristina Pirosa, Anastasios Stathis, Davide Rossi, et al.
Pageof 14